Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 14,000 new ordinary shares of 1p in the Company at a price of 6 pence per New Share pursuant to the exercise of 14,000 warrants.

Application has been made for the 14,000 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 21 April 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,418,342,375 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,418,342,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact: